

## **Precision Prebiotics**


Alteration in gut composition, "selectivity" and host benefit are impacted by prebiotic structure.


Precision prebiotics have a higher specificity when feeding gut bacteria, leading to more selective alterations in the microbiome.

## Key Advantages:


- ✓ Low dose
   ✓ Minimal side effects (bloating, discomfort)
- ✓ Selective growth of good bacteria
- ✓ Pleiotropic (anti-inflammatory) effects

AIDP




















































## **Study Significance and Future Implications**


How might it impact on clinical practice in the foreseeable future?


- These findings suggest that depletion of immunomodulatory gut microorganisms contributes to severe COVID-19 disease.
- The dysbiotic gut microbiota that persists after disease resolution could be a factor in developing
  persistent symptoms and/or multisystem inflammation syndromes that occur in some patients
  after clearing the virus.
- Bolstering of beneficial gut species depleted in COVID-19 could serve as a novel avenue to
  mitigate severe disease, underscoring importance of managing patients' gut microbiota during
  and after COVID-19.

AIDP


19































## BeautyOLIGO<sup>®</sup> Supports Skin Tone - Hyperpigmentation Inhibitory effect of galactooligosaccharide on skin pigmentation. Prev. Nutr. Food Sci. 2019;24(3):321-326 In vitro study: • effects of BeautyOLIGO on melanin accumulation in B16F10 cell model Randomized, Double-Blind, Placebo Controlled Trial: • N=79 (mean age 50-51 yrs) • Placebo Group (n=39): 1 g dextrin 2x daily • GOS Group (n=40): 1 g BeautyOLIGO 2x daily

- 12 weeks
  Changes in melanin index and erythema index

28

Variable	Group –	Time (week)			
		Baseline	4	8	12
MI	Placebo (N=40)	160.08±4.28	159.53±4.05	154.72±3.92	155.65±4.13
	GOS (N=39)	161,84±5,57	158,42±4,48	145,85±4,94*****	145,55±5,03*****
EI	Placebo (N=40)	279,89±8,15	270.56±7.34	270.13±7.93	273.62±7.17
	GOS (N=39)	282.85±7.53	258.81±9.04***	253.57±9.30****	253.85±8.11****
oy a repea ndicated b	ted measure ANOVA fo	ollowed by Bonferroni nd <sup>11</sup> P<0.01 between	-adjusted pairwise comp	change from baseline at arisons within groups. Sig at each week by <i>t</i> -test).	nificant differences were

